About Hologic, Inc.
https://www.hologic.comHologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
CEO
Stephen P. MacMillan
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2008-04-03 | Forward | 2:1 |
| 2005-12-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 791
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Argus Research
Buy
Citigroup
Buy
Evercore ISI Group
Outperform
RBC Capital
Outperform
Morgan Stanley
Equal Weight
Stephens & Co.
Equal Weight
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:26.21M
Value:$1.97B
BLACKROCK INC.
Shares:23.1M
Value:$1.74B
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:21.55M
Value:$1.62B
Summary
Showing Top 3 of 988
About Hologic, Inc.
https://www.hologic.comHologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q4-2025 | $1.05B ▲ | $402.1M ▲ | $187.3M ▼ | 17.85% ▼ | $0.84 ▼ | $316.5M ▼ |
| Q3-2025 | $1.02B ▲ | $322M ▼ | $194.9M ▲ | 19.04% ▲ | $0.87 ▲ | $334M ▲ |
| Q2-2025 | $1.01B ▼ | $384.3M ▲ | $-17.4M ▼ | -1.73% ▼ | $-0.08 ▼ | $76.8M ▼ |
| Q1-2025 | $1.02B ▲ | $350.7M ▲ | $201M ▲ | 19.67% ▲ | $0.87 ▲ | $352M ▲ |
| Q4-2024 | $988M | $327.7M | $178.6M | 18.08% | $0.76 | $328.1M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q4-2025 | $2.2B ▲ | $9.01B ▲ | $3.97B ▲ | $5.05B ▲ |
| Q3-2025 | $1.88B ▲ | $8.81B ▲ | $3.96B ▲ | $4.84B ▲ |
| Q2-2025 | $1.62B ▼ | $8.55B ▼ | $3.93B ▼ | $4.62B ▼ |
| Q1-2025 | $1.97B ▼ | $8.73B ▼ | $3.96B ▼ | $4.77B ▼ |
| Q4-2024 | $2.33B | $9.16B | $4.03B | $5.13B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $194.9M ▲ | $343.3M ▲ | $-4.3M ▲ | $-40.1M ▲ | $305.7M ▲ | $330.5M ▲ |
| Q2-2025 | $-17.4M ▼ | $169.4M ▼ | $-324.3M ▼ | $-201.7M ▲ | $-352.6M ▲ | $129.2M ▼ |
| Q1-2025 | $201M ▲ | $189.3M ▼ | $-22M ▲ | $-537M ▼ | $-378.1M ▼ | $142.3M ▼ |
| Q4-2024 | $178.6M ▼ | $367M ▼ | $-595.7M ▼ | $-56.8M ▲ | $-278.9M ▼ | $336.7M ▼ |
| Q3-2024 | $194.5M | $405.8M | $-42.6M | $-103.8M | $259.1M | $371.9M |
Revenue by Products
| Product | Q3-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Breast Health | $390.00M ▲ | $370.00M ▼ | $360.00M ▼ | $370.00M ▲ |
 Diagnostics | $440.00M ▲ | $470.00M ▲ | $450.00M ▼ | $450.00M ▲ |
 Gyn Surgical | $170.00M ▲ | $170.00M ▲ | $160.00M ▼ | $180.00M ▲ |
 Skeletal Health | $20.00M ▲ | $20.00M ▲ | $30.00M ▲ | $30.00M ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 Asia Pacific | $70.00M ▲ | $60.00M ▼ | $60.00M ▲ | $60.00M ▲ |
 Europe | $130.00M ▲ | $150.00M ▲ | $150.00M ▲ | $150.00M ▲ |
 Rest of World | $50.00M ▲ | $50.00M ▲ | $50.00M ▲ | $60.00M ▲ |
 UNITED STATES | $750.00M ▲ | $740.00M ▼ | $760.00M ▲ | $760.00M ▲ |
CEO
Stephen P. MacMillan
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2008-04-03 | Forward | 2:1 |
| 2005-12-01 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 791
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Argus Research
Buy
Citigroup
Buy
Evercore ISI Group
Outperform
RBC Capital
Outperform
Morgan Stanley
Equal Weight
Stephens & Co.
Equal Weight
Grade Summary
Showing Top 6 of 13
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:26.21M
Value:$1.97B
BLACKROCK INC.
Shares:23.1M
Value:$1.74B
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:21.55M
Value:$1.62B
Summary
Showing Top 3 of 988